NASDAQ:BNGO Bionano Genomics - BNGO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bionano Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.96 -0.01 (-0.25%) (As of 02/3/2023 11:47 AM ET) Add Compare Share Share Today's Range$1.87▼$1.9750-Day Range$1.40▼$2.2252-Week Range$1.16▼$4.35Volume2.58 million shsAverage Volume6.65 million shsMarket Capitalization$583.45 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bionano Genomics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside232.5% Upside$6.50 Price TargetShort InterestBearish17.92% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.46Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.39) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.57 out of 5 starsMedical Sector895th out of 1,029 stocksAnalytical Instruments Industry25th out of 27 stocks 3.5 Analyst's Opinion Consensus RatingBionano Genomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Bionano Genomics has a forecasted upside of 232.5% from its current price of $1.96.Amount of Analyst CoverageBionano Genomics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.92% of the outstanding shares of Bionano Genomics have been sold short.Short Interest Ratio / Days to CoverBionano Genomics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Bionano Genomics has recently increased by 2.76%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBionano Genomics does not currently pay a dividend.Dividend GrowthBionano Genomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNGO. Previous Next 1.4 News and Social Media Coverage News SentimentBionano Genomics has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bionano Genomics this week, compared to 2 articles on an average week.Search Interest72 people have searched for BNGO on MarketBeat in the last 30 days. This is an increase of 31% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added Bionano Genomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -46% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bionano Genomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Bionano Genomics is held by insiders.Percentage Held by InstitutionsOnly 26.91% of the stock of Bionano Genomics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bionano Genomics are expected to grow in the coming year, from ($0.39) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bionano Genomics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bionano Genomics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBionano Genomics has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bionano Genomics (NASDAQ:BNGO) StockBionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.Read More Receive BNGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionano Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address BNGO Stock News HeadlinesJanuary 23, 2023 | marketbeat.comNVIDIA Outlook Improving: Watchlist Candidate for 2023 (BNGO)With less than three weeks gone so far this year, we’re once again excited about NVIDIA’s stock, and aren’t the only ones.February 2, 2023 | finance.yahoo.comBionano’s Symposium 2023 Featured Record Numbers of Presentations Demonstrating Applications of OGM Across Cell Bioprocessing and Constitutional Genetic Disease and Cancer ResearchFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.February 2, 2023 | nasdaq.comBlackRock Increases Position in BioNano Genomics (BNGO)January 30, 2023 | seekingalpha.comBionano's Balance Sheet Challenges: History Repeating ItselfJanuary 26, 2023 | finance.yahoo.comAre Medical Stocks Lagging Bionano Genomics (BNGO) This Year?January 25, 2023 | americanbankingnews.comBionano Genomics, Inc. (NASDAQ:BNGO) Sees Significant Increase in Short InterestJanuary 24, 2023 | finance.yahoo.comBionano Laboratories Expands its Clinical Testing Menu with Launch of its First OGM-Based Laboratory Developed Test (LDT) for Hematological MalignanciesFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 23, 2023 | finance.yahoo.comBionano Announces Launch of Next-Generation Versions of its Reagent Kits and Chip Consumable, Along with Updates to its Instrument Control and Bionano Access Software for the Optical Genome Mapping WorkflowJanuary 20, 2023 | finance.yahoo.comBionano Genomics Announces the Final Speaker Lineup for Symposium 2023 with 30 OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Research ApplicationsJanuary 18, 2023 | finance.yahoo.comBionano Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal TestingJanuary 12, 2023 | finanznachrichten.deBionano Genomics: Bionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIAJanuary 12, 2023 | finance.yahoo.comBionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIAJanuary 11, 2023 | finance.yahoo.comBionano Announces Publication from Institut Curie Showing Utility of OGM for Detection of HRD in Breast CancerJanuary 10, 2023 | finance.yahoo.comBionano Genomics Announces 2023 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer ApplicationsJanuary 6, 2023 | finance.yahoo.comBionano Genomics to Host Strategy Day on February 2, 2023 in New York CityJanuary 5, 2023 | finance.yahoo.comBionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 ResultsDecember 30, 2022 | finance.yahoo.com10 Best High-Risk High-Reward Stocks To Buy NowDecember 22, 2022 | finance.yahoo.comThis Innovative Growth Stock Could Double or More in 2023December 9, 2022 | seekingalpha.comBionano announces publication that highlights potential of optical genome mappingDecember 9, 2022 | finance.yahoo.comMulti-Center Research Study Illustrates How OGM Can Potentially Result in More Patients Qualifying for Treatments in LeukemiaDecember 8, 2022 | finance.yahoo.comBionano Genomics Announces American Society of Hematology (ASH) Annual Meeting Presentations Featuring OGM Utility Across Blood Cancer Research ApplicationsDecember 1, 2022 | finance.yahoo.comBears are Losing Control Over Bionano Genomics, Inc. (BNGO), Here's Why It's a 'Buy' NowNovember 28, 2022 | finance.yahoo.comBionano Genomics to Acquire Purigen Biosystems to Enable Further Simplified and Accelerated DNA Isolation for Optical Genome Mapping (OGM) and Address Difficult Sample Types in New Applications with Isotachophoresis (ITP) on the Ionic Purification SystemNovember 21, 2022 | benzinga.comCapitalGainsReport Sector Spotlight: Healthcare Penny Stocks On The Move (ARDX, WHSI, BNGO)November 21, 2022 | finance.yahoo.comPublication Shows Utility of OGM in Solid Tumor Research with Study on Detection of Complex Genomic Rearrangements in Prostate CancerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BNGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionano Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address BNGO Company Calendar Last Earnings8/03/2021Today2/03/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BNGO CUSIPN/A CIK1411690 Webwww.bionanogenomics.com Phone(858) 888-7600FaxN/AEmployees299Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.50 High Stock Price Forecast$12.00 Low Stock Price Forecast$3.50 Forecasted Upside/Downside+230.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,430,000.00 Net Margins-451.42% Pretax Margin-473.39% Return on Equity-38.48% Return on Assets-34.11% Debt Debt-to-Equity Ratio0.01 Current Ratio6.51 Quick Ratio5.77 Sales & Book Value Annual Sales$17.98 million Price / Sales32.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book1.68Miscellaneous Outstanding Shares296,920,000Free Float293,361,000Market Cap$583.45 million OptionableNot Optionable Beta2.25 Key ExecutivesRobert Erik HolmlinPresident, CEO, Secretary & DirectorMark OldakowskiChief Operating OfficerChristopher StewartChief Financial & Accounting OfficerAlka ChaubeyChief Medical OfficerJason PriarChief Commercial OfficerKey CompetitorsQuanterixNASDAQ:QTRXAkoya BiosciencesNASDAQ:AKYACue HealthNASDAQ:HLTHSeerNASDAQ:SEERNautilus BiotechnologyNASDAQ:NAUTView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 137,600 shares on 2/2/2023Ownership: 0.000%SG Americas Securities LLCSold 6,427 shares on 2/2/2023Ownership: 0.044%ProShare Advisors LLCBought 6,320 shares on 2/2/2023Ownership: 0.013%Zurcher Kantonalbank Zurich Cantonalbank Bought 6,442 shares on 2/1/2023Ownership: 0.025%Versor Investments LPSold 60,923 shares on 1/30/2023Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions BNGO Stock - Frequently Asked Questions Should I buy or sell Bionano Genomics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionano Genomics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNGO shares. View BNGO analyst ratings or view top-rated stocks. What is Bionano Genomics' stock price forecast for 2023? 3 analysts have issued twelve-month price objectives for Bionano Genomics' stock. Their BNGO share price forecasts range from $3.50 to $12.00. On average, they anticipate the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 229.9% from the stock's current price. View analysts price targets for BNGO or view top-rated stocks among Wall Street analysts. How have BNGO shares performed in 2023? Bionano Genomics' stock was trading at $1.46 at the beginning of 2023. Since then, BNGO stock has increased by 34.9% and is now trading at $1.97. View the best growth stocks for 2023 here. When is Bionano Genomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our BNGO earnings forecast. How were Bionano Genomics' earnings last quarter? Bionano Genomics, Inc. (NASDAQ:BNGO) announced its quarterly earnings results on Tuesday, August, 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.02. The company earned $3.86 million during the quarter, compared to analysts' expectations of $3.30 million. Bionano Genomics had a negative net margin of 451.42% and a negative trailing twelve-month return on equity of 38.48%. What guidance has Bionano Genomics issued on next quarter's earnings? Bionano Genomics updated its FY 2022 earnings guidance on Saturday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $27.70 million-$28.00 million, compared to the consensus revenue estimate of $27.44 million. What is R. Erik Holmlin's approval rating as Bionano Genomics' CEO? 17 employees have rated Bionano Genomics Chief Executive Officer R. Erik Holmlin on Glassdoor.com. R. Erik Holmlin has an approval rating of 73% among the company's employees. 71.0% of employees surveyed would recommend working at Bionano Genomics to a friend. What other stocks do shareholders of Bionano Genomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bionano Genomics investors own include Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Aeterna Zentaris (AEZS) and Organigram (OGI). When did Bionano Genomics IPO? (BNGO) raised $16 million in an IPO on the week of August 20th 2018. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. Roth Capital Partners and Maxim Group served as the underwriters for the IPO and LifeSci Capital was co-manager. What is Bionano Genomics' stock symbol? Bionano Genomics trades on the NASDAQ under the ticker symbol "BNGO." Who are Bionano Genomics' major shareholders? Bionano Genomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (0.19%), Inspire Advisors LLC (0.12%), Simplex Trading LLC (0.00%), SG Americas Securities LLC (0.04%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and Versor Investments LP (0.02%). Insiders that own company stock include R Erik Holmlin and Yvonne Linney. View institutional ownership trends. How do I buy shares of Bionano Genomics? Shares of BNGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bionano Genomics' stock price today? One share of BNGO stock can currently be purchased for approximately $1.97. How much money does Bionano Genomics make? Bionano Genomics (NASDAQ:BNGO) has a market capitalization of $584.93 million and generates $17.98 million in revenue each year. The company earns $-72,430,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. How many employees does Bionano Genomics have? The company employs 299 workers across the globe. How can I contact Bionano Genomics? Bionano Genomics' mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The official website for the company is www.bionanogenomics.com. The company can be reached via phone at (858) 888-7600 or via email at arr@lifesciadvisors.com. This page (NASDAQ:BNGO) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.